Welcome to our dedicated page for Tivic Health Systems SEC filings (Ticker: TIVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tivic Health Systems, Inc. (TIVC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Tivic files a range of reports with the U.S. Securities and Exchange Commission that outline its immunotherapeutics strategy, licensing agreements, financings and governance matters.
Investors can review Tivic’s current reports on Form 8‑K, which describe material events such as the exclusive license and amended and restated license agreement for the TLR5 agonist programs Entolimod and Entolasta, the transfer of investigational new drug applications (INDs) for Entolimod, and the acquisition of contract development and manufacturing organization (CDMO) assets used to form Velocity Bioworks. Other 8‑K filings detail executive employment agreements, equity incentive plan amendments, transfer agent changes and shareholder meeting results.
Registration statements like the S‑1/A shed light on Tivic’s status as an emerging growth and smaller reporting company, the registration of common stock and warrants held by selling stockholders, and the structure of preferred stock and convertible securities. These documents help explain how Tivic raises capital to support its biologics and bioelectronic programs.
On this page, Stock Titan surfaces Tivic’s 10‑K annual reports and 10‑Q quarterly reports when available, which typically include risk factors, management’s discussion and analysis, and detailed descriptions of the company’s dual‑platform strategy in biologics and bioelectronic medicine. Form 4 and related ownership filings, when present, can be used to monitor insider equity transactions and incentive awards tied to Tivic’s equity plans.
Stock Titan enhances Tivic’s filings with AI-generated summaries that highlight key terms in license agreements, financing structures, and manufacturing commitments, helping readers quickly identify items such as Entolimod development milestones, Velocity Bioworks obligations, and voting outcomes from shareholder meetings. Real-time EDGAR updates ensure that new Tivic filings appear promptly, while structured views make it easier to navigate between 8‑K events, registration statements and periodic reports for a more complete understanding of TIVC’s regulatory and corporate history.
Tivic Health Systems director Christina Rizopoulos Valauri made an open-market purchase of company stock. She bought 19,000 shares of Tivic Health Systems, Inc. Common Stock on April 1, 2026 at a price of $0.9478 per share. After this transaction, she directly owns 19,000 shares.
Tivic Health Systems, Inc. files its annual report outlining a major pivot from bioelectronic consumer devices to a late-stage biopharmaceutical strategy centered on Entolimod, a TLR5 agonist for Acute Radiation Syndrome and oncology-related complications such as neutropenia and thrombocytopenia. The company licensed Entolimod and next‑generation compound Entolasta in 2025 and created a CDMO subsidiary, Velocity Bioworks, supported by a financing package exceeding $90 million. Tivic reports net losses, an accumulated deficit and states there is substantial doubt about its ability to continue as a going concern, while also disclosing a material weakness in internal controls due to limited accounting staff. As of March 17, 2026, it had 2,877,926 shares outstanding and 52 employees, and is pursuing ARS and oncology opportunities, including potential U.S. government procurement for the Strategic National Stockpile.
Tivic Health Systems reported its full-year 2025 results and highlighted a major strategic shift into immunotherapy centered on its Entolimod™ platform and next-generation molecule Entolasta™. Management described 2025 as a defining year, securing global rights to Entolimod and advancing regulatory and development readiness.
The company is prioritizing Entolimod for acute radiation syndrome while planning to extend into oncology supportive care, initially targeting neutropenia via physician-sponsored trials expected later in the year. Through its Velocity Bioworks subsidiary, Tivic is vertically integrating manufacturing, positioning it as a standalone CDMO to both lower internal costs and pursue third-party revenue opportunities.
Tivic Health Systems, Inc. reported that Nasdaq has notified the company it is not in compliance with the Nasdaq Capital Market’s minimum bid price rule because its common stock closed below $1.00 per share for at least 30 consecutive business days. The stock remains listed for now, and Tivic has 180 days from March 19, 2026, through September 15, 2026, to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. If it fails to do so, Nasdaq may grant an additional 180‑day grace period if other listing standards are met and Tivic indicates an intent to cure the deficiency; otherwise the shares could be subject to delisting, with a right of appeal.
Tivic Health Systems, Inc. Chief Financial Officer Lisa G. Wolf exercised restricted stock units that converted into 92 shares of Common Stock on March 18, 2026. The shares were acquired at a conversion price of $0.00 per share, reflecting compensation rather than an open-market purchase.
Following the transactions, Wolf directly holds 526 shares of Common Stock and 643 Restricted Stock Units. The filing notes these figures reflect a 1-for-17 reverse stock split completed on March 7, 2025, and that the RSUs vest over three years from December 18, 2023.
Tivic Health Systems, Inc., through its wholly owned subsidiary Velocity Bioworks, Inc. (VBI), has committed to new facilities in San Antonio, Texas via three long-term agreements. VBI entered an eight-year lease for an approximately 8,024 sq ft microbial building with aggregate base rent of about $5.34 million and a one-time option to extend for five years, plus an exclusive option to purchase the building and property for $12.5 million during the first 24 months. VBI also signed a 102‑month lease for an approximately 20,144 sq ft mammalian facility with aggregate base rent of about $6.29 million. In addition, VBI agreed to a 110‑month sublease for about 8,122 sq ft of office space at the same property, with starting monthly base rent of $31,044.94; this office will serve as the company’s new principal executive office. For all three agreements, VBI will also pay its share of operating expenses, taxes and utilities.
Tivic Health Systems, Inc. canceled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on March 12, 2026. The meeting was originally held and then adjourned on February 19, 2026 because too few shares were represented to form a quorum.
As of the December 29, 2025 record date, 2,525,778 shares of common stock were entitled to vote, but stockholders holding less than one-third of this capital stock were present or represented by proxy. On March 11, 2026, the Board adopted a resolution to cancel the adjourned meeting and withdraw all proposals described in the related proxy materials.
Tivic Health Systems, Inc. announced a leadership transition, appointing Michael K. Handley as Chief Executive Officer and a member of the board of directors, effective immediately. Handley, a life sciences executive with more than two decades of commercialization and regulatory experience, has been the company’s Chief Operating Officer and President of Tivic Biopharma since February 2025.
Jennifer Ernst resigned as Chief Executive Officer effective March 2, 2026 and will step down from the board on March 5, 2026. Under a Separation Agreement, she will receive an aggregate cash payment of $325,000 over a 12‑month severance period, continued COBRA coverage during that period, continued vesting of her unvested equity awards over the severance period, and $50,000 in restricted common stock, subject to shareholder approval. The company emphasized that her resignation was not due to any dispute or disagreement regarding operations, policies or practices.
Tivic Health Systems, Inc. reporting persons 3i, Tumim Stone Capital LLC, 3i Management LLC and Maier Joshua Tarlow disclose beneficial ownership positions tied to convertible instruments and warrants that are subject to a 9.99% ownership blocker.
Based on 2,535,509 shares outstanding as of February 5, 2026, the filing reports 3i beneficially owns 276,187 shares (including 47,055 directly held shares and an aggregate 229,132 issuable upon exercise/conversion subject to the blocker) and Tumim beneficially owns 229,132 shares. The filing states that 3i delivered a notice on February 20, 2026 to increase the Blockers from 4.99% to 9.99%, effective 61 days thereafter.
Tivic Health Systems filed an amended Form 8-K to add audited financial statements for Scorpius Holdings and unaudited pro forma results related to its December 2025 asset acquisition through subsidiary Velocity Bioworks. Scorpius generated $6.24 million of 2024 revenue but reported a net loss attributable to Scorpius of $32.8 million and an accumulated deficit of $287.2 million.
Scorpius ended 2024 with cash and cash equivalents of $1.03 million and total assets of $39.2 million against total liabilities of $37.5 million, including $16.0 million of related-party convertible promissory notes and a warrant liability of $2.10 million. Its auditors highlighted recurring losses and limited cash as raising substantial doubt about Scorpius’s ability to continue as a going concern.